Avro­bio shares blast­ed af­ter tri­al up­date sours out­look on gene ther­a­py for Fab­ry dis­ease

Avro­bio made the leap on­to Nas­daq a few months ago and then pro­ceed­ed to run the ta­ble large­ly on a snap­shot of ef­fi­ca­cy for its lead gene ther­a­py to treat Fab­ry dis­ease. On Mon­day, though, an up­dat­ed look at a key da­ta point sent in­vestors run­ning, col­laps­ing the share price.

By the end of the day on Mon­day Avro­bio’s stock $AVRO had been beat­en down 52%, wip­ing out hun­dreds of mil­lions of dol­lars in mar­ket cap.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.